Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CBM-588 by Miyarisan Pharmaceutical for Metastatic Renal Cell Carcinoma: Likelihood of Approval
CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...
Data Insights
CBM-588 by Miyarisan Pharmaceutical for Lung Cancer: Likelihood of Approval
CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase III for Lung Cancer. According to GlobalData, Phase...